Entering text into the input field will update the search result below

Sanofi-Regeneron Dupixent meets main goal of reducing itch in phase 3 skin disease trial

Jan. 19, 2022 7:29 AM ETSanofi (SNY) StockREGNBy: Ravikash Bakolia, SA News Editor

Healthcare and medical concept. Female scratching the itch on her hand, cause of itching from skin diseases, dry skin, allergy, chemical, allergic to detergent or dishwashing liquid and dermatitis, insect bites, burned, drug. Health problem.

ipopba/iStock via Getty Images

  • A second phase 3 trial of Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals' (NASDAQ:REGN) medicine Dupixent (dupilumab) met its main and key secondary goals, showing the drug significantly reduced itch and skin lesions in patients with prurigo nodularis compared

Recommended For You

More Trending News

About SNY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SNY--
Sanofi